TAVR Market Shifting Into High Gear
Executive Summary
Momentum is building in the burgeoning and rapidly evolving transcatheter aortic valve replacement (TAVR) market. With a growing body of clinical evidence, the potential for expanded indications in lower-risk patients, and more favorable reimbursement on the horizon, the TAVR market is shifting into high gear, with solid, double-digit growth ahead.
You may also be interested in...
TAVR Market: Next-Generation Devices Seek To Optimize Outcomes
The market opportunity for TAVR is significant, with 2013 sales totaling $303.4 million in the US and $765 million outside the US, and those numbers are expected to grow to an estimated $1.29 billion and $1.63 billion, respectively, by 2018. Edwards and Medtronic dominate the worldwide market at present, but other companies are expected to make inroads with next-generation devices designed to optimize outcomes.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.